Vivodyne’s Human Tissue Factory Wins Endpoints 11 2026, Promising Faster Drug Testing

Vivodyne was announced as the winner of the Endpoints 11 2026 competition for its human tissue factory technology.

The platform creates human tissue constructs that can be used in preclinical drug testing, aiming to bridge the gap between laboratory studies and clinical outcomes.

According to the competition summary, the approach could streamline the drug development process by providing more predictive models, potentially reducing reliance on animal testing.

If adopted widely, the technology may help accelerate timelines for new therapies and improve confidence in early‑stage results.